Abstract:Recent safety issues involving non-active implantable medical devices (NAIMDs) have highlighted the need for better pre-market and post-market evaluation. Some stakeholders have argued that certain features of medicine safety evaluation should also be applied to medical devices. Our objectives were to compare the current processes and methodologies for the assessment of NAIMD safety profiles with those for medicines, identify potential gaps, and make recommendations for the adoption of new methodologies for the ongoing benefit–risk monitoring of these devices throughout their entire life cycle. A literature review served to examine the current tools for the safety evaluation of NAIMDs and those for medicines. We searched MEDLINE using these two categories. We supplemented this search with Google searches using the same key terms used in the MEDLINE search. Using a comparative approach, we summarized the new product design, development cycle (preclinical and clinical phases), and post-market phases for NAIMDs and drugs. We also evaluated and compared the respective processes to integrate and assess safety data during the life cycle of the products, including signal detection, signal management, and subsequent potential regulatory actions. The search identified a gap in NAIMD safety signal generation: no global program exists that collects and analyzes adverse events and product quality issues. Data sources in real-world settings, such as electronic health records, need to be effectively identified and explored as additional sources of safety information, particularly in some areas such as the EU and USA where there are plans to implement the unique device identifier (UDI). The UDI and other initiatives will enable more robust follow-up and assessment of long-term patient outcomes. The safety evaluation system for NAIMDs differs in many ways from those for drugs, but both systems face analogous challenges with respect to monitoring real-world usage. Certain features of the drug safety evaluation process could, if adopted and adapted for NAIMDs, lead to better and more systematic evaluations of the latter.

[Reasons for discontinuing intravenous therapy associated with the time of in-situ permanence of peripheral venous devices].

Expert Consensus on Quality Management System of Bioprinting Medical Devices Special Requirements

Supervision System of AI-based Software As a Medical Device

Implementation of Quality by Design in the Program of Safety Re-evaluation of TCM Injections

The Current Problems of Regulation of Medical Devices and Countermeasures

The stability of memories during brain remodeling: A perspective

[Research Status of Nanomaterial Medical Device and Discussion on Biological Evaluation]

[Research on the issues in the process of post-market surveillance for medical devices based on the typical case analysis]

Exploring how to Improve the Quality Control of Medical Instrument Clinical Trials

[Supervision, Administration and Standard Research Related to Tissue Engineered Medical Products].

[The current situation review of medical device risk management]

Risk Management in Medical Device Maintenance Workshops

[Critical Control Points and Case Studies in the Production of Metal Additive Manufacturing Medical Device]

Biomechanical measurements of the porcine lens capsule.

Application the Risk-Based Maintenance for Optimizing the Overall Medical Devices Safety

Evaluating the Safety Profile of Non-Active Implantable Medical Devices Compared with Medicines

Telemedicine, the effect of nurse‐initiated telephone follow up, on health status and health‐care utilization in COPD patients: A randomized trial

Case study — Risk management for medical devices (based on ISO 14971)

Accelerating medical device biocompatibility evaluation: An industry perspective

[A Medical Devices Management Information System Supporting Full Life-Cycle Process Management].

Resilience of a Supply Chain-Based Economic Evaluation of Medical Devices From an Industry Perspective